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INTRODUCTION
According to statistical data, head and neck squamous 
cell carcinomas (HNSSCs), on the scale of incidence of 
all human tumors, are on the 6th position, wheras 50% of 
these tumors are located in oral region. Despite develop­
ment in the last decades in the prevention and efficiant 
surgical resections, as well as adequate radio and chemo­
therapy, five­year survival rate still remains the same 
(about 50%) [1]. Lack of simptomatology, rapid growth 
and early metastasis are the reasons of the bad course of 
disease. Different scrinning methods and introduction  of 
molecular­genetic analyses could be of great importance 
during the preclinical, asimptomatic stage of disease to 
provide possible better prognosis.
One of the pivotal molecular­genetics markers, intro­
duced in the control of proliferation in about 60% tumors 
of the head and neck, is p53 tumor suppressor gene [2]. 
Normal function of p53 gene could be lost by exposing 
oral mucosa to different cancerogenic agetns (e.g. smok­
ing, alcohol...). p53 gene named as „guardian of genome”, 
has a role to stop the proliferation of cell with genetic 
lesions, giving the time to cells to repair damaged genetic 
material. Contrary, cells with unrepaired lesions under 
control of normal p53 gene would be involved in apopto­
sis [3]. Various stimuli, such as: cytotoxic stimuli, ioniz­
ing and UV radiation, might initiate activation of normal 
p53 gene, through realizing its tumor suppressor func­
tion. Moreover, cells with mutated p53 gene treated with 
genotoxic agents, could pass through cell cycle uncon­
trolled, and consequently numerous lesions in DNA might 
be accumulated. The most common p53 gene mutations 
are point mutations in exons 5, 6, 7, and 8.
The aim of this study was to determine the frequency 
of p53 gene mutation, i.e. the role of this gene in patho­
genesis of oral squamous cell carcinoma.
MATERIALS AND METHODS
A genomic DNA isolated from paraffin blocks of oral SCCs 
was used in this study. The specimens of tumor tissue after 
histopathology analysis precisely were cut out, separated 
from surrounding normal tissue and contributed to extrac­
tion of DNA using phenol/chloroform method.
From the 60 analyzed OSCCs, the most of them (26) 
were located in lower lip (43%), than, with decreased 
frequency, in the following region: tongue – 16 (26.7%), 
floor of mouth – 8 (13%), bucal mucosa – 3 (5%), mandib­
ula – 3 (5%) and 1 sample was obtained from other region 
of oral cavity. Using clinical parameters TNM status was 
determined (Table 1). Also, the degree of cell differentia­
tion was estimated in all tumor specimens, using grading 
classification: G1 – well; G2 – moderate; G3 – poor; G4 – 
undiferentiated. 45 out of 60 were primary tumors, and 
15 were recurring. According to anamnesis data, analyzed 
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specimens were dominantly obtained from older male 
patients, i.e. 33 patients had more than 33 years, while 
47 were male.
The presence of point mutation in exon 5, 6, 7, and 
8, using polymerase chain reaction (PCR) and single 
strand conformation polymorphism (SSCP) method, was 
analyzed in all SCCs tumor specimens. Point mutations 
could be detected by means of SSCP, according to mobil­
ity of the single strand of DNA in nodenaturating environ­
ment. To confirm mutations detected by SSCP method, 
5 specimens underwent to sequencing of exon 5 on ABI 
Prism 310 Genetic Analyzer.
Before performing sequencial analysis, using Qiagen 
kit, PCR amplicon was cleaned. PCR reaction mixture 
consisted of the following components: BigDye Terminator 
3.1 (8 µl), PCR amplicon­exon 5 (10 ng), „forward” primer 
5’TTCCTCTTCCTACAGTACTC3’ (3.2 pmol) and H2O 
(to 20 µl). PCR reaction was performed as follows: initial 
denaturation at 96°C (1 minute) and 25 cycles of ampli­
fication at 96°C (10 seconds), 50°C (5 seconds) and 60°C 
(4 minutes). After PCR reaction, samples were treated 
with isopropanol to discard not incorporated nucle­
otide, than mixed with formamid and in the next step 
were denaturated at 96°C 2 minutes. Following denatur­
ation, samples were sequenced in ABI capillary system. 
Obtained sequences were compared with base of nucleo­
tide sequence – NCBI GenBank.
RESULTS
Mutational analyses of p53 gene in exons 5, 6, 7 and 8, 
showed the presence of point mutation in 60% of analyzed 
samples. Summarizing all mutations of p53 gene, 8 muta­
tion were detected in exon 5, 12 in exon 6, 16 in exon 7 
and 13 in exon 8. A higher frequency of mutations was 
obtained in exons 7 and 8 (60%), than in exon 5 and 6. 
The presence of point mutations in exon 5 of p53 gene, 
detected by SSCP technique, was confirmed by sequenc­
ing of the 5 randomly chosen samples (Table 2).
By analyzing distribution of oral SCCs with p53 muta­
tion in relation to clinical and histopathological parame­
Table 1. Distribution of oral squamocellular carcinomas in relation to 
TNM status and grade of diferentiation
Tabela 1. Raspodela oralnih skvamocelularnih karcinoma na osnovu 







T1 (<2 cm) 3
T2 (2-4 cm) 24
















Table 2. Nucleotide sequence of exon 5, p53 gene






Insertion T in codon 33, CGC Insertion T in codon 40, CAG







Supstitution in codon 27, CCG→CCT  (Pro→Pro)
Supstitucija u kodonu 27, CCG→CCT  (Pro→Pro)
Supstitution in intron, A→T







Supstitution in codon 41, TCA→TTA  (Ser→Leu)
Supstitucija u kodonu 41, TCA→TTA  (Ser→Leu)
Supstitution in codon 48, GTG→GTC (Val→Val)







Deletion in codon 23, GAT  and codon, 24 TCC







Insertion T in codon 22, GTT
Insercija T u kodonu 22, GTT
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ters, higher frequency of mutation was observed in moder­
ate/poor differentiated carcinoma as well as in the higher 
clinical stages of the carcinoma. The difference in distri­
bution of p53 affected gene was not established between 
primary and recurring carcinoma, and also between carci­
noma with and without metastasis in the lymphatic nodes.
DISCUSSION
It is known fact that about 95% mutations that lead to 
inactivation of p53 gene are located in highly conserved, 
DNA binding domain (from 5 to 9 exon). The aim of this 
study was to analyze a role of exon 5, 6, 7 and 8 in muta­
tional spectra of p53 gene in oral SCC. According to these 
analyses, a higher frequency of mutations was observed 
in exons 7 and 8 (60%) than in exons 5 and 6, what is in 
agreement with results of other authors [4]. In order to 
confirm and detect type of mutations, sequencing anal­
ysis of exon 5 was done for five specimens. Interestingly, 
different types of point mutations were located at nucle­
otide G in particulary codon. In various tumor samples 
substitution G→T and G→C, deletion G and insertion at 
guanine (G) nukleotide were found. Whatever the type 
of the detected mutations and their effect to structure of 
altered p53 protein, changes in nucleotide sequence were 
dominantly present at G. The numerous studies that inves­
tigated a role of carcinogenic agens in development of the 
head, neck and lung carcinoma, showed that carcinogens 
present in tobacco smoke bind to G and frequently induce 
point mutation in DNA binding region of p53 gene [5, 6]. 
Also, many studies proved the connection between carci­
nogenic factors (UV radiation, alcohol, exposure to phys­
ical/chemical mutagenes) and specific muational spectra 
of p53 gene [7, 8].
In accordance with the most of reported data in the 
world, this study showed 60% of analyzed carcinoma 
with p53 gene mutation [9]. The relationship between 
p53 mutation and its altered protein was shown in many 
immunohistochemical studies by detecting mutated p53 
protein with prolonged half­life in nucleus or citoplasm 
[10]. Beside to histopathological and clinical parameters, 
mutational status of p53 gene may have a role as an addi­
tional prognostic marker in oral SCCs. It is confirmed that 
tumors with p53 mutation are more resistent to radio­ and 
chemotherapy, due to absence of p53­induced apoptosis 
[11]. On the other hand, some data showed no association 
between normal p53 gene and better therapy response. 
Therefore, it is possible that many molecules are included 
in apoptotic pathway [12].
In this study, a higher incidence of p53 mutation in 
higher clinical stages was shown, indicating its impor­
tant role in patogenesis of oral carcinoma. Opposite to 
these results, absence of p53 mutation in 40% cases, 
could be attributed to p53­independent mechanism of 
carcinogenesis.
CONCLUSION
A high incidence of p53 mutation in analyzed samples 
without doubt emphasized its important role in develop­
ment and progresion of OSCC.
ACKNOWLEDGMENT
This study was financed by Serbian Ministry of Science 
and Technology (Grant No. 1454042).
REFERENCES
1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. 
CA Cancer J Clin. 2000; 50:7-33.
2. Yao L, Iwai M, Furuta I. Correlation of bcl2 and p53 expression with 
the clinico pathological features in tongue squamous cell carcino-
mas. Oral Oncol. 1999; 35:56-62.
3. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degra-
dation and stabilizes p53: ARF-INK4a locus deletion impairs both 
the Rb and p53 tumor suppression pathways. Cell. 1998; 92:725-34.
4. Chaves A, Cherubini K, Herter N, Furian R, Santos D, Squier C, et 
al. Characterization of p53 gene mutation in a Brazilian population 
with oral squamous cell carcinomas. Int J Oncol. 2004; 24:295-303.
5. Boyle JO, Hakim J, Koch W, Van der Riet P, Hruban RH, Roa RA, et 
al. The incidence of p53 mutations increases with progression of 
head and neck cancer. Cancer Res. 1993; 53:4477-80.
6. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation 
of benzo[a]pyrene adducts at lung cancer mutational hotspots in 
p53. Science. 1996; 274:430-2.
7. Kress S, Sutter C, Strickland PT, Mukhtar H, Schweizer J, Schwarz 
M. Carcinogen-specific mutational pattern in the p53 gene in ul-
traviolet B radiation-induced squamous cell carcinomas of mouse 
skin. Cancer Res. 1992; 52:6400-13.
8. Regezi JA, Jordan RC. Oral cancer in the molecular age. J Calif Dent 
Assoc. 2001; 29:578-84.
9. Bosch FX, Ritter D, Enders C, Flechtenmacher C, Abel U, Dietz A, 
et al. Head and neck tumor sites differ in prevalence and spec-
trum of p53 alterations but these have limited prognostic value. 
Int J Cancer. 2004; 111:530-8.
10. Nagler RM, Kerner H, Laufer D, Ben-Elizer S, Minkov I, Itzhak OB. 
Squamous cell carcinoma of the tongue: the prevalence and prog-
nostic roles of p53, Bcl-2, c-erbB2 and apoptotic rate as related to 
clinical and pathological characteristic in a retrospective study. 
Cancer Letters. 2002; 186:137-50.
11. Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi 
T, et al. p53 alterations predict tumor response to neoadjuvant che-
motherapy in head and neck squamous cell carcinoma: a prospec-
tive series. J Clin Oncol. 2000; 18:1465-73.
12. Gudkov AV, Komarova EA. The role of p53 in determining sensi-
tivity to radiotherapy. Nat Rev Cancer. 2003; 3:117-29.
Address for correspondence
Branka Popović 
Institute for Human Genetics 
School of Dentistry 
Dr Subotića 1, 11000 Belgrade 
Serbia 
Phone: +381 (0)11 2683 943
Email: brankapo@verat.net
Stomatološki glasnik Srbije, vol. 56, sv. 4, 2009.174
Mutacioni status gena p53 u oralnim skvamocelularnim 
karcinomima
Branka Popović1, Biljana Jekić2, Drago Jelovac3, Ivana Novaković2
1Institut za humanu genetiku, Stomatološki fakultet, Univerzitet u Beogradu, Beograd, Srbija;
2Institut za humanu genetiku, Medicinski fakultet, Univerzitet u Beogradu, Beograd, Srbija;
3Klinika za maksilofacijalnu hirurgiju, Stomatološki fakultet, Univerzitet u Beogradu, Beograd, Srbija
UVOD
Pre ma sta ti stič kim na la zi ma u sve tu, skva mo ce lu lar ni kar ci no­
mi gla ve i vra ta (SCK) se na ska li in ci den ci je svih tu mo ra kod 
lju di na la ze na še stom me stu, pri če mu je 50% tu mo ra ovog re­
gi o na lo ka li zo va no u oral noj re gi ji. Upr kos po ma ku u pre ven­
ci ji i le če nju ostva re nom po sled njih de ce ni ja u po gle du pe to­
go di šnje sto pe pre ži vlja va nja bo le sni ka (ko ja je oko 50%), zna­
ča jan na pre dak još ni je ostva ren [1]. Skrom na simp to ma to lo­
gi ja, brz rast i ra ne me ta sta ze su raz lo zi ne pred vi dlji vog kli nič­
kog to ka bo le sti. Pre ven tiv na pri me na raz li či tih skri ning­me to­
da i uvo đe nje mo le ku lar no ge ne tič kih ana li za u ot kri va nje kar­
ci no ma u pret kli nič koj, asimp to mat skoj fa zi mo gli bi sva ka ko 
obez be di ti i bo lju prog no zu.
Je dan od ključ nih mo le ku lar no ge ne tič kih mar ke ra ko ji je 
uklju čen u kon tro lu pro li fe ra ci je kod oko 60% tu mo ra gla ve 
i vra ta je tu mor­su pre sor ski gen p53 [2]. Do gu bit ka nor mal­
ne funk ci je ovo ga ge na mo že do ći usled dej stva raz li či tih kan­
ce ro ge nih agen sa (du van ski dim, al ko hol,...) ko ji ma je oral na 
mu ko za če sto iz lo že na. TP53 gen je ozna čen još i kao „ču var 
ge no ma” i ima ulo gu u za u sta vlja nju pro li fe ra ci je će li ja sa gen­
skim le zi ja ma, ka ko bi se po pra vi la ošte će nja na sled nog ma te­
ri ja la. U su prot nom, će li je s neo po ra vlje nim le zi ja ma tre ba da 
se pod vrg nu pro gra mu apop to ze [3]. Raz li či ti sti mu lu si, kao što 
su dej stvo ci to tok sič nih an ti tu mor skih agen sa, jo ni zu ju ćeg i ul­
tra lju bi ča stog zra če nja, mo gu ta ko đe do ve sti do ak ti va ci je nor­
mal nog ge na p53, od no sno do re a li za ci je nje go ve tu mor­su pre­
sor ske funk ci je. Me đu tim, će li je s mu ti ra nim ge nom p53 ko­
je su iz lo že ne dej stvu ge no tok sič nih agen sa ne kon tro li sa no će 
pro la zi ti kroz će lij sku ci klus, što za po sle di cu ima na go mi la va­
nje broj nih le zi ja na DNK. Naj če šći tip gen skih mu ta ci ja ko je 
po ga đa ju gen p53 su tač ka ste mu ta ci je u eg zo ni ma 5, 6, 7 i 8.
Cilj ra da je bio da se utvr di za stu plje nost tač ka stih mu ta ci­
ja u re gi o nu ge na p53 ko ji se ve zu je za DNK, od no sno pro ce ni 
ulo ga ovo ga ge na u pa to ge ne zi oral nih skva mo ce lu lar nih kar­
ci no ma (OSCK).
MATERIJAL I METODE RADA
U stu di ji je ko ri šće na ge nom ska DNK izo lo va na iz pa ra fin skih 
blo ko va OSCK. Uzor ci tu mor skog tki va su na kon hi sto pa to lo­
ške ana li ze pre ci zno ise če ni i odvo je ni od okol nog uka lu plje­
nog nor mal nog tki va, a za tim pod vrg nu ti me to di fe nol­hlo ro­
form eks trak ci je DNK.
Od ukup nog bro ja ana li zi ra nih OSCK (60) naj vi še tu mo ra 
(26) je bi lo lo ka li zo va no na do njoj usni (43%); sle de lo ka li za­
ci je na je zi ku – 16 (26%), po du usta – 8 (13%), bu kal noj slu­
zo ko ži – 3 (5%) i man di bu li – 3 (5%). Po je dan uzo rak (1%) je 
do bi jen iz pre de la mak si le, gin gi ve, oro fa rink sa i me kog nep­
ca. Za sve OSCK je na osno vu kli nič kih pa ra me ta ra de fi ni san 
tzv. TNM sta tus (ve li či na tu mo ra, lo kal ne i uda lje ne me ta sta ze) 
(Ta be la 1). Po red od re đi va nja TNM sta tu sa, kla si fi ka ci ja kar­
ci no ma je iz vr še na i na osno vu ste pe na di fe ren ci ja ci je ma lig­
nih će li ja, i to na če ti ri stup nja: G1 – do bro di fe ren ci ra ne, G2 – 
sred nje di fe ren ci ra ne, G3 – sla bo di fe ren ci ra ne i G4 – ne di fe­
ren ci ra ne će li je. Od ukup nog bro ja uzo ra ka, 45 su pred sta vlja­
li pri mar ne tu mo re, dok su 15 bi li re ci di vi. Po sma tra ju ći sta ro­
snu i pol nu struk tu ru bo le sni ka, do mi ni ra li su sta ri ji mu škar­
ci, pri če mu su 33 bo le sni ka ima la vi še od 60 go di na, a ukup­
no je bi lo 47 mu ška ra ca.
Kod svih OSCK su ana li zi ra ne tač ka ste mu ta ci je u eg zo ni ma 
5, 6, 7 i 8 ge na p53 me to dom lan ča ne re ak ci je po li me ra ze (en­
gl. polyme­ra­se­chain­re­ac­tion­–­PCR) i po li mor fi zma jed no­
lan ča nih frag me na ta DNK (engl. sin­gle­strand­con­for­ma­tion­
polymorp­hism­–­SSCP). SSCP se za sni va na elek tro fo ret skoj 
po kre tlji vo sti jed no lan ča ne DNK u ne de na tu ri šu ćoj sre di ni. Ka­
ko bi se po tvr di le mu ta ci je ot kri ve ne ovom me to dom, kod pet 
uzo ra ka je do dat no se kven ci ran eg zon 5 ge na p53 na apa ra tu 
ABI­Prism­310­Ge­ne­tic­Analzyer.
Pre se kven ci ra nja PCR am pli fi ka ti su pre či šće ni pri me nom 
ki ta Qi­a­gen. Re ak ci o nu sme su PCR či ni le su sle de će kom po­
nen te: BigDye­Ter­mi­na­tor­3.1 (8 μl), PCR am pli fi kat eg zon 5 
(10 ng), „uz vod ni” praj mer 5’TTCCTCTTCCTA CAG TACTC3’ 
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(3,2 pmol) i vo da (do 20 µl). Pro gram PCR za se kven ci ra nje bio 
je sle de ći: ini ci jal na de na tu ra ci ja na 96°C (je dan mi nut) i 25 ci­
klu sa am pli fi ka ci je na 96°C (10 se kun di), 50°C (pet se kun di) i 
60°C (če ti ri mi nu ta). Na kon PCR uzor ci su pre či šće ni izo pro­
pa no lom da bi se od stra ni li ne in kor po ri sa ni obe le že ni nu kle­
o ti di, a za tim je do dat for ma mid, po sle če ga su uzor ci de na tu­
ri sa ni na 96°C dva mi nu ta. Po sle de na tu ra ci je uzor ci su po sta­
vlje ni u ABI (engl. ap­plied­bi­osystems), ka pi lar ni si stem za se­
kven ci ra nje. Do bi je ne se kven ce upo re đe ne su s Me đu na rod nom 
ba zom po da ta ka (NCBI­Gen­Bank).
REZULTATI
Mu ta ci o nom ana li zom tač ka ste mu ta ci je su usta no vlje ne u 60% 
ana li zi ra nih uzo ra ka OSCK. Ot kri ve no je osam mu ta ci ja u eg­
zo nu 5, 12 u eg zo nu 6, 16 u eg zo nu 7 i 13 u eg zo nu 8. U 13 uzo­
ra ka ot kri ve ne su po dve mu ta ci je u raz li či tim eg zo ni ma. Ve­
ća uče sta lost mu ta ci ja do bi je na je u eg zo ni ma 7 i 8 (60%). Tač­
ka ste mu ta ci je u eg zo nu 5 ge na p53, ot kri ve ne po mo ću SSCP, 
po tvr đe ne su di rekt nim se kven ci ra njem pet slu čaj no oda bra­
nih uzo ra ka (Ta be la 2).
Ana li zi ra ju ći ras po de lu OSCK sa mu ta ci jom ge na p53 u od­
no su na kli nič ke i hi sto pa to lo ške pa ra me tre, usta no vlje na je ve­
ća uče sta lost mu ta ci ja kod sred nje i sla bo di fe ren ci ra nih i kar­
ci no ma vi ših kli nič kih sta di ju ma. Raz li ka u sto pi mu ta ci ja ni­
je usta no vlje na ni iz me đu pri mar nih kar ci no ma i re ci di va, ni ti 
iz me đu kar ci no ma sa me ta sta za ma u lim fnim čvo ro vi ma i kar­
ci no ma bez ovih me ta sta za.
DISKUSIJA
Ka ko je 95% mu ta ci ja ge na p53 ko je se od ra ža va ju na inak ti va­
ci ju pro te i na p53 lo ci ra no u vi so ko kon zer vi ra nom re gi o nu ko ji 
se ve zu je za DNK, cilj ove stu di je bio je da se ana li zi ra udeo eg­
zo na 5, 6, 7 i 8 u mu ta ci o nom spek tru ge na p53 u OSCK. Usta­
no vlje na je ve ća uče sta lost mu ta ci ja u eg zo ni ma 7 i 8 (60%), što 
su za be le ži li i dru gi auto ri [4]. Ra di po tvr de za stu plje no sti i od­
re đi va nja ti pa mu ta ci ja, kod pet uzo ra ka je se kven ci ran eg zon 
5. Uoče no je da se raz li či ti ti po vi tač ka stih mu ta ci ja naj če šće 
de ša va ju na nu kle o ti du G od re đe nog ko do na. Ta ko se kod raz­
li či tih uzo ra ka ot kri va ju sup sti tu ci je G→T i G→C, de le ci ja G i 
in ser ci ja is pred G. Da kle, bez ob zi ra na tip mu ta ci je i njen efe­
kat na struk tu ru iz me nje nog pro te i na p53, pro me ne unu tar ge­
na se de ša va ju u ni vou nu kle o ti da G. Broj ne stu di je ko je su is­
pi ti va le ulo gu kan ce ro ge nih agen sa u raz vo ju kar ci no ma gla ve 
i vra ta i plu ća po ka za le su da mu ta ge ni du va na ve zi va njem za 
nu kle o tid G iza zi va ju tač ka ste mu ta ci je, naj če šće u re gion ge na 
p53 ko ji se ve zu je za DNK [5, 6]. U mno gim is tra ži va nji ma je 
ta ko đe do ka za na ve za iz me đu dej stva mu ta ge nih fak to ra, kao 
što su ul tra lju bi ča sto zra če nje, zlo u po tre ba al ko ho la, iz la ga nje 
fi zič kim i he mij skim mu ta ge ni ma na rad nom me stu, i spe ci­
fič nog mu ta ci o nog spek tra ge na p53 [7, 8].
U skla du s ve ći nom re zul ta ta stu di ja pu bli ko va nih u svet­
skoj li te ra tu ri, u ovom is tra ži va nju su u 60% ana li zi ra nih kar­
ci no ma po tvr đe ne mu ta ci je ge na p53 [9]. Da su mu ta ci je ovo­
ga ge na pra će ne i iz me nje nim pro te i nom p53 po ka zu ju raz li či­
te imu no hi sto he mij ske stu di je ko je su ot kri le mu ti ra ni pro tein 
p53 u je dru ili ci to pla zmi usled nje go vog pro lon gi ra nog po lu­
ži vo ta [10]. Da kle, po red hi sto pa to lo ških i kli nič kih pa ra me ta­
ra, mu ta ci o ni sta tus ge na p53 mo že ima ti ulo gu do dat nog prog­
no stič kog po ka za te lja kod OSCK. Ne ki auto ri su utvr di li da su 
kar ci no mi sa mu ta ci jom ge na p53 re zi stent ni ji na zrač nu te ra­
pi ju i he mi o te ra pi ju usled in hi bi ci je me ha ni zma apop to ze p53 
[11]. Ipak, još ima do sta kon tra dik tor no sti ko je se od no se na 
ve zu iz me đu pri su stva nor mal nog pro te i na p53 i od go va ra ju­
ćeg te ra pij skog od go vo ra zbog mo guć no sti da se apop to za za­
u sta vi na vi še raz li či tih sig nal nih pu te va [12].
ZAKLJUČAK
Vi so ka uče sta lost mu ta ci ja ge na p53 u is pi ta nim uzor ci ma ne­
sum nji vo uka zu je na va žnu ulo gu ovog kon tro lo ra će lij skog ci­
klu sa u na stan ku i pro gre si ji kar ci no ma oral ne re gi je.
NAPOMENA
Rad je fi nan si ra lo Mi ni star stvo za na u ku i teh no lo ški raz voj Re­
pu bli ke Sr bi je (pro je kat br. 1454042).
